Merck & Company Inc (MRK)vsRapid Micro Biosystems Inc (RPID)
MRK
Merck & Company Inc
$109.18
-1.60%
HEALTHCARE · Cap: $274.03B
RPID
Rapid Micro Biosystems Inc
$2.30
-6.50%
HEALTHCARE · Cap: $112.59M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 193460% more annual revenue ($65.01B vs $33.59M). MRK leads profitability with a 28.1% profit margin vs -140.3%. MRK earns a higher WallStSmart Score of 59/100 (C).
MRK
Buy59
out of 100
Grade: C
RPID
Avoid33
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-13.2%
Fair Value
$96.48
Current Price
$109.18
$12.70 premium
Margin of Safety
-20.3%
Fair Value
$3.49
Current Price
$2.30
$1.19 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 37 in profit
Strong operational efficiency at 32.8%
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Generating 1.8B in free cash flow
Revenue surging 37.3% year-over-year
Areas to Watch
Weak financial health signals
Expensive relative to growth rate
Earnings declined 19.3%
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -86.8% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 28.1% and operating margin at 32.8%.
Bull Case : RPID
The strongest argument for RPID centers on Revenue Growth. Revenue growth of 37.3% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are Piotroski F-Score, PEG Ratio, EPS Growth.
Bear Case : RPID
The primary concerns for RPID are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
MRK profiles as a value stock while RPID is a hypergrowth play — different risk/reward profiles.
RPID carries more volatility with a beta of 1.60 — expect wider price swings.
RPID is growing revenue faster at 37.3% — sustainability is the question.
MRK generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (59/100 vs 33/100), backed by strong 28.1% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Rapid Micro Biosystems Inc
HEALTHCARE · MEDICAL DEVICES · USA
Rapid Micro Biosystems Inc (RPID) is a pioneering biotechnology firm dedicated to transforming microbiological quality control within the pharmaceutical and biotechnology sectors. The company leverages cutting-edge automated growth-based microbial detection technologies to enhance the accuracy and efficiency of microbial testing, thereby ensuring stringent product quality and compliance with regulatory standards. Positioned at the forefront of an expanding market that demands swift and dependable quality assurance solutions, Rapid Micro is poised to lead the advancement of innovative testing methodologies critical to maintaining safety and excellence in regulated environments.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?